news
5 Warning Signals Behind FDA’s 1,700‑Plus Semaglutide Reports
Over 1,700 adverse event reports have been filed for compounded semaglutide, indicating hidden risks in off-label GLP-1 therapy. These filings, submitted through the FDA’s MedWatch system, span mild gastrointestinal upset to severe hypoglycemia and cardiac complications. Understanding this data is essential for clinicians, regulators, and pharmaceutical teams. Medical